In last trading session, Adc Therapeutics SA (NYSE:ADCT) saw 0.32 million shares changing hands with its beta currently measuring 1.54. Company’s recent per share price level of $1.63 trading at -$0.04 or -2.40% at ring of the bell on the day assigns it a market valuation of $157.60M. That closing price of ADCT’s stock is at a discount of -230.06% from its 52-week high price of $5.38 and is indicating a premium of 14.72% from its 52-week low price of $1.39.
For Adc Therapeutics SA (ADCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Adc Therapeutics SA (NYSE:ADCT) trade information
Upright in the red during last session for losing -2.40%, in the last five days ADCT remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.63 price level, adding 7.91% to its value on the day. Adc Therapeutics SA’s shares saw a change of -18.09% in year-to-date performance and have moved 1.24% in past 5-day. Adc Therapeutics SA (NYSE:ADCT) showed a performance of -4.12% in past 30-days.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 79.62% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would drop -329.45% in reaching the projected high whereas dropping to the targeted low would mean a loss of -329.45% for stock’s current value.
Adc Therapeutics SA (ADCT) estimates and forecasts
This year revenue growth is estimated to rise 4.79% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 19.01M for the same. And 3 analysts are in estimates of company making revenue of 19.12M in the next quarter. Company posted 16.79M and 18.05M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -10.46% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 41.98% while estimates for its earnings growth in next 5 years are of 26.22%.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
REDMILE GROUP, LLC is the top institutional holder at ADCT for having 15.27 million shares of worth $48.25 million. And as of 2024-06-30, it was holding 15.9568 of the company’s outstanding shares.
The second largest institutional holder is PROSIGHT MANAGEMENT, LP, which was holding about 9.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.0009 of outstanding shares, having a total worth of $30.24 million.
On the other hand, iShares Russell 2000 ETF and Fidelity Small Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 2.17 shares of worth $3.54 million or 2.24% of the total outstanding shares. The later fund manager was in possession of 826.48 shares on Oct 31, 2024 , making its stake of worth around $1.35 million in the company or a holder of 0.85% of company’s stock.
